(Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, ...

HyBryte demonstrates more rapid and robust treatment response compared toValchlor® during 12-week treatment course PRINCETON, N.J., April 2, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) ...

(RTTNews) - Antengene Corporation Limited (6996.HK) announced that China National Medical Products Administration or NMPA has approved the investigational new drug application for the Phase Ib/II ...

The Trump administration’s latest effort to lower drug costs is expanding to biosimilars, medications that are highly similar to biologic drugs made with or isolated from living organisms such as ...

ART denotes antiretroviral therapy, Ct cycle threshold, HIV human immunodeficiency virus, MPXV mpox virus, NA not available, and PCR polymerase chain reaction. Age ranges are provided to protect the ...

The impact of adherence to NCCN and BCLC treatment guidelines on survival in HCC: A single center study. 10 key areas highlighting differences identified between HICs and LMICs. MDT development ...

This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium. This abstract does not include a full text component.

The Presidential Symposium "Eyes to the future" will feature the first-ever presentation of the clinical trial portion of the PIONeeR Project (Precision Immuno-Oncology for advanced Non-Small Cell ...

NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children ...